Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples